Literature DB >> 23908447

New features of disease after diagnosis in 6 forms of systemic vasculitis.

Peter C Grayson1, David Cuthbertson, Simon Carette, Gary S Hoffman, Nader A Khalidi, Curry L Koening, Carol A Langford, Kathleen Maksimowicz-McKinnon, Paul A Monach, Philip Seo, Ulrich Specks, Steven R Ytterberg, Peter A Merkel.   

Abstract

OBJECTIVE: To quantify the occurrence of features of vasculitis that initially present after diagnosis in 6 types of primary vasculitis.
METHODS: Standardized collection of data on 95 disease manifestations in 6 vasculitides, including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA), polyarteritis nodosa (PAN), giant cell arteritis (GCA), and Takayasu arteritis (TAK), was obtained within a set of multicenter longitudinal, observational cohorts. For each form of vasculitis, the frequency of disease-specific manifestations at diagnosis was compared to the cumulative frequency of each manifestation. The percentage of patients who initially developed severe manifestations after diagnosis, defined as organ- or life-threatening in the small and medium vessel vasculitides (GPA, MPA, EGPA, PAN) and as ischemic/vascular in the large vessel vasculitides (GCA, TAK), was reported.
RESULTS: Out of 838 patients with vasculitis, 490 (59%) experienced ≥ 1 new disease manifestation after diagnosis. On average, patients with vasculitis experienced 1.3 new manifestations after diagnosis (GPA = 1.9, MPA = 1.2, EGPA = 1.5, PAN = 1.2, GCA = 0.7, and TAK = 1.0). New severe manifestations occurred after diagnosis in 224 (27%) out of 838 patients (GPA = 26%, MPA = 19%, EGPA = 21%, PAN = 23%, GCA = 24%, and TAK = 44%). Timing of onset of new manifestations was not significantly associated with disease duration.
CONCLUSION: A majority of patients with vasculitis develop new disease features after diagnosis, including a substantial number of new, severe manifestations. Ongoing assessment of patients with established vasculitis should remain broad in scope.

Entities:  

Keywords:  EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS; GIANT CELL ARTERITIS; GRANULOMATOSIS WITH POLYANGIITIS; MICROSCOPIC POLYANGIITIS; POLYARTERITIS NODOSA; TAKAYASU ARTERITIS; VASCULITIS

Mesh:

Year:  2013        PMID: 23908447      PMCID: PMC4292850          DOI: 10.3899/jrheum.121473

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  40 in total

Review 1.  Prognostic factors in systemic necrotizing vasculitis of the polyarteritis nodosa group--a review of 45 cases.

Authors:  P R Fortin; M G Larson; A K Watters; C A Yeadon; D Choquette; J M Esdaile
Journal:  J Rheumatol       Date:  1995-01       Impact factor: 4.666

2.  Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome.

Authors:  Renato A Sinico; Lucafrancesco Di Toma; Umberto Maggiore; Paolo Bottero; Antonella Radice; Cinzia Tosoni; Chiara Grasselli; Laura Pavone; Gina Gregorini; Stefano Monti; Micol Frassi; Filomena Vecchio; Caterina Corace; Emanuela Venegoni; Carlo Buzio
Journal:  Arthritis Rheum       Date:  2005-09

Review 3.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference.

Authors:  J C Jennette; R J Falk; K Andrassy; P A Bacon; J Churg; W L Gross; E C Hagen; G S Hoffman; G G Hunder; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1994-02

4.  Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients.

Authors:  L Guillevin; B Durand-Gasselin; R Cevallos; M Gayraud; F Lhote; P Callard; J Amouroux; P Casassus; B Jarrousse
Journal:  Arthritis Rheum       Date:  1999-03

5.  Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort.

Authors:  E L Matteson; K N Gold; D A Bloch; G G Hunder
Journal:  Am J Med       Date:  1996-08       Impact factor: 4.965

6.  Disease pattern in cranial and large-vessel giant cell arteritis.

Authors:  A Brack; V Martinez-Taboada; A Stanson; J J Goronzy; C M Weyand
Journal:  Arthritis Rheum       Date:  1999-02

7.  Current status of Takayasu arteritis in India.

Authors:  S Jain; S Kumari; N K Ganguly; B K Sharma
Journal:  Int J Cardiol       Date:  1996-08       Impact factor: 4.164

8.  Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients.

Authors:  L Guillevin; P Cohen; M Gayraud; F Lhote; B Jarrousse; P Casassus
Journal:  Medicine (Baltimore)       Date:  1999-01       Impact factor: 1.889

9.  The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern.

Authors:  C Salvarani; S E Gabriel; W M O'Fallon; G G Hunder
Journal:  Ann Intern Med       Date:  1995-08-01       Impact factor: 25.391

10.  Takayasu arteritis in Japan.

Authors:  K Koide
Journal:  Heart Vessels Suppl       Date:  1992
View more
  14 in total

Review 1.  Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature.

Authors:  Alice Sy; Nader Khalidi; Natasha Dehghan; Lillian Barra; Simon Carette; David Cuthbertson; Gary S Hoffman; Curry L Koening; Carol A Langford; Carol McAlear; Larry Moreland; Paul A Monach; Philip Seo; Ulrich Specks; Antoine Sreih; Steven R Ytterberg; Gert Van Assche; Peter A Merkel; Christian Pagnoux
Journal:  Semin Arthritis Rheum       Date:  2015-07-26       Impact factor: 5.532

2.  Defining the nasal transcriptome in granulomatosis with polyangiitis (Wegener's).

Authors:  Peter C Grayson; Katrina Steiling; Michael Platt; Jeffrey S Berman; Xiaohui Zhang; Ji Xiao; Yuriy O Alekseyev; Gang Liu; Paul A Monach; Mariana J Kaplan; Avrum Spira; Peter A Merkel
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

3.  Polyarteritis nodosa presenting as profuse gastrointestinal bleeding.

Authors:  Gaurang Nandkishor Vaidya; Arman Khorasani-Zadeh; Savio John
Journal:  BMJ Case Rep       Date:  2014-02-06

Review 4.  [Cardiovascular and hemostaseological view of retinal vascular occlusions].

Authors:  H Seidel; E Stegemann; C Heiss
Journal:  Ophthalmologe       Date:  2014-01       Impact factor: 1.059

5.  Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis.

Authors:  Alicia Rodriguez-Pla; Roscoe L Warner; David Cuthbertson; Simon Carette; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Larry W Moreland; Christian Pagnoux; Philip Seo; Ulrich Specks; Antoine G Sreih; Steven R Ytterberg; Kent J Johnson; Peter A Merkel; Paul A Monach
Journal:  J Rheumatol       Date:  2019-09-01       Impact factor: 4.666

Review 6.  Recent advances in Takayasu's arteritis.

Authors:  Fatma Alibaz-Öner; Sibel Zehra Aydın; Haner Direskeneli
Journal:  Eur J Rheumatol       Date:  2015-03-01

Review 7.  Orbital Vasculitides-Differential Diagnosis.

Authors:  Gabriela M Espinoza; Jessica L Liu
Journal:  Curr Rheumatol Rep       Date:  2019-09-05       Impact factor: 4.592

Review 8.  Eosinophils in vasculitis: characteristics and roles in pathogenesis.

Authors:  Paneez Khoury; Peter C Grayson; Amy D Klion
Journal:  Nat Rev Rheumatol       Date:  2014-07-08       Impact factor: 20.543

Review 9.  Unmet Needs in the Pathogenesis and Treatment of Vasculitides.

Authors:  Francesco Muratore; Giulia Pazzola; Alessandra Soriano; Nicolò Pipitone; Stefania Croci; Martina Bonacini; Luigi Boiardi; Carlo Salvarani
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 10.  Diagnosis and differential diagnosis of large-vessel vasculitides.

Authors:  Gokhan Keser; Kenan Aksu
Journal:  Rheumatol Int       Date:  2018-09-17       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.